| Identification | Back Directory | [Name]
TPO agonist 1 | [CAS]
1033040-23-1 | [Synonyms]
TPO agonist 1
1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] | [Molecular Formula]
C25H22N8O2 | [MOL File]
1033040-23-1.mol | [Molecular Weight]
466.49 |
| Hazard Information | Back Directory | [Uses]
TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia[1]. | [Biological Activity]
TPO agonist 1 is a TPO agonist that acts as a promoter of thrombopoiesis and megakaryocytopoiesis for the study of thrombocytopenia. | [in vivo]
The thrombopoietin (TPO) receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes, and can increases platelet counts, decrease bleeding events and reduce the need for adjunctive or rescue treatments. The TPO receptor agonists are well-tolerated, though uncertainty remains regarding the risk of thromboembolism and bone marrow fibrosis[2]. | [target]
| [References]
[1] Jerome Francis Hayes. Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics. 6 November 2008. WO2008134338A1.
[2] Siegal D et al. Thrombopoietin receptor agonists in primary immune thrombocytopenia.
et al. Semin Hematol. 2013 Jan;50 Suppl 1:S18-21 DOI:10.1053/j.seminhematol.2013.03.005 |
|
|